Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. Given the wide use of both prescribed and over the counter drugs, DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. This is exemplified by the hepatotoxicity of acetaminophen (APAP) overdose, a major cause of ALF because of its extensive worldwide use as an analgesic. Despite intensive efforts utilising current animal and in vitro models, the mechanisms involved in the hepatotoxicity of APAP are still not fully understood. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing. We present novel insights and discuss major players in APAP pathophysiology, and describe emerging in vitro and in vivo pre-clinical models, as well as advanced imaging and in silico technologies, which may improve prediction of clinical outcomes of DILI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current knowledge on exosome biogenesis and release
Hessvik, N. P., & Llorente, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2595-9 · Cited by 2,362
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Vascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170 · cited 1×
“152 153 – 155 As an alternative to primary hepatocytes, iPSC-derived cultures of HLCs have several applications for early preclinical hepatotoxicity assessment and drug screening in 2D and 3D culture systems.”
Background3D bioprinting of collagen to rebuild components of the human heart
Lee, A., Hudson, A. R., Shiwarski, D. J., Tashman, J. W., Hinton, T. J., Yerneni, S., Bliley, J. M., Campbell, P. G., & Feinberg, A. W. (2019) · Science · doi:10.1126/science.aav9051 · Cited by 1,782 · cited 1×
“167 Many novel integrative bioengineering approaches have been adopted, with new designs and innovations continuing to evolve at a rapid pace.”
BackgroundInduced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525 · cited 1×
“129,130 134 Early protocols for HLC generationwere based on addition of stage-speci fi c morphogenic cues mimicking hepatic embryonic development.”
Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation
Kalra, H., Simpson, R. J., Ji, H., Aikawa, E., Altevogt, P., Askenase, P., Bond, V. C., Borràs, F. E., Breakefield, X., Budnik, V., et al. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001450 · Cited by 1,367 · cited 1×
“81 In the liver, the fi rst descriptions of hepatocyte-derived vesicles were obtained from primary culture of rat hepatocytes, 82 and isolated hepatic stem cell cultures.”
BackgroundHighly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Richardson, D. S., & Lichtman, J. W. (2015) · Cell · doi:10.1016/j.cell.2015.06.067 · Cited by 1,095
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Liver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Cited by
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
“Indeed, hepatocyte proliferation is severely inhibited in chronic liver diseases, including MASLD, alcoholic liver disease, and chronic exposure to hepatotoxins (Fernandez-Checa et al. 2021; Michalopoulos 2013; Sancho-Bru et al. 2012).”
BackgroundMicrofluidic Liver-on-a-Chip for Preclinical Drug Discovery
Fu, J., Qiu, H., & Tan, C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041300 · Cited by 42
Biomimetic hepatic lobules from three-dimensional imprinted cell sheets
Wang, J., Huang, D., Chen, H., & Zhao, Y. (2024) · Science Bulletin · doi:10.1016/j.scib.2024.02.030 · Cited by 37
Guo, K., & van den Beucken, T. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01317-2 · Cited by 28
Development of an AI model for DILI-level prediction using liver organoid brightfield images
Tan, S., Ding, Y., Wang, W., Rao, J., Cheng, F., Zhang, Q., Xu, T., Hu, T., Hu, Q., Ye, Z., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08205-6 · Cited by 26
“By providing an early-stage, in vitro platform for hepatotoxicity evaluation, our model might signi fi cantly reduce reliance on animal models, which often struggle to predict DILI, particularly idiosyncratic DILI 28 .”
Metadata
- Authors
- Fernandez-Checa, J. C., Bagnaninchi, P., Ye, H., Sancho-Bru, P., Falcon-Perez, J. M., Royo, F., Garcia-Ruiz, C., Konu, O., Miranda, J., Lunov, O., Dejneka, A., Elfick, A., McDonald, A., Sullivan, G. J., Aithal, G. P., Lucena, M. I., Andrade, R. J., Fromenty, B., Kranendonk, M., Cubero, F. J., & Nelson, L. J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 75
- Issue
- 4
- Pages
- 935-959
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3173906377
- Cited by
- 126
- References
- 47
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. https://app.cochat.ai/papers/10.1016/j.jhep.2021.06.021
- The paper
- Fernandez-Checa, J. C., Bagnaninchi, P., Ye, H., Sancho-Bru, P., Falcon-Perez, J. M., Royo, F., Garcia-Ruiz, C., Konu, O., Miranda, J., Lunov, O., Dejneka, A., Elfick, A., McDonald, A., Sullivan, G. J., Aithal, G. P., Lucena, M. I., Andrade, R. J., Fromenty, B., Kranendonk, M., . . . Nelson, L. J. (2021). Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2021.06.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.